We are on the cusp of a groundbreaking shift
- A turning point has arrived. The medical community now acknowledges the critical importance of pre-symptomatic T1D, reflected in the assignment of ICD-10 codes, underscoring the need for clinical oversight.
- Momentum is building. The first therapy proven to delay the onset of symptomatic T1D has been approved in some countries, and it is progressing through European regulatory processes.
- The time for action is now. Clinical trials for disease-modifying therapies are expanding rapidly, and identifying individuals with early T1D has never been more urgent.
To seize this momentum and push the boundaries of early-stage T1D detection, INNODIA - thanks to its Strategic Supporters - is driving a pan European initiative:
The INNODIA Family & Friends Early T1D Detection Program
The INNODIA Detect is available to all INNODIA clinical site Members and provides harmonized guidance for early T1D detection and monitoring, including:
- Master protocols for islet autoantibody (IAb) detection and monitoring of IAb+ individuals, developed in alignment with international guidelines [1].
- Access to a centralized data repository (INNODIA eCRF) for streamlined data collection.
- Matchmaking support to connect clinical trials' Sponsors with the clinical sites monitoring pre-symptomatic T1D individuals.
Our goal?
To ensure every clinical site interested in IAb screening has a clear, actionable roadmap to follow.
By equipping clinical sites with tools and frameworks, INNODIA is ensuring that people with pre-symptomatic T1D are identified, monitored, and offered clinical trials or therapies when availableoffered the opportunity to benefit from the next wave of T1D therapies.
Are you ready to be part of this revolution in T1D care?
- If your site is already an INNODIA Member, we will contact you to explore your interest
- If your site is not an INNODIA Member but interested in joining us in this transformative effort, become a Member or contact us at detect@innodia.org
